Phagos, a biotechnology firm headquartered in Paris, recently secured a €25 million Series A funding round. This achievement signals the company’s intent to advance its innovative phage therapy platform, which leverages artificial intelligence and microbiology to treat bacterial diseases. Co-founded by Alexandros Pantalis and Adèle James in 2021, Phagos aims to address the pressing threat of antibiotic resistance in animal health by offering adaptable bacteriophage solutions. These phages are designed to effectively counter pathogens that evolve, paving the way for more sustainable treatments in veterinary applications.
Why is AI Crucial for Phage Development?
The integration of AI in Phagos’ platform is essential for tailoring precise phage therapies at scale. By analyzing the entire genomes of phages and bacteria, AI can predict interactions, enabling the creation of highly specific treatments. This is particularly significant for combating antimicrobial resistance, a crisis foreseen to cause millions of fatalities and substantial economic impacts by 2050. In parallel, the steady decline in antibiotic efficiency for livestock since 2000 accentuates the need for alternative strategies like those offered by Phagos.
How Does Phagos Plan to Leverage New Funding?
With the fresh influx of capital, Phagos intends to broaden its deployment of phage-therapy solutions in veterinary medicine. Additionally, the company aims to accelerate research and development to enhance its patented AI technology, further refining the precision and adaptability of its treatments. Part of the funding will also support the expansion of Phagos’ team, a move critical for fostering platform growth and preparing for market introduction.
Previously, Phagos achieved critical milestones by obtaining regulatory authorization for marketing its personalized phage-based veterinary products. This groundbreaking step highlighted regulatory support for innovative treatments and set the stage for potential expansion into human health applications. The co-founders see these regulatory advancements as pivotal in positioning phage therapy as a standard for tackling bacterial infections globally.
“This Series A funding enhances our ability to fulfill our mission of transforming how bacterial infections are treated in the veterinary world,” said Alexandros Pantalis.
The participation of major investors like CapAgro, Hoxton Ventures, CapHorn, and Demeter underscores the confidence the financial community has in Phagos’ technology and strategic vision. Insights from these investors could further catalyze the commercialization and scaling of the company’s platform.
“We are poised to redefine the standard for phage therapies. Our advanced AI platform sets us apart in addressing a global challenge,” added Adèle James.
Phagos’ journey underscores the increasing interest and investment in alternative biotechnological solutions for bacterial treatment resistance. As they make strides with AI and microbiology, the potential for advancements in both animal and human health seems promising. The challenges will likely involve navigating regulatory landscapes and scaling these complex therapies effectively for various markets. The success of Phagos’ strategic execution could set a new precedent in biopharma, underscoring the essential role of technology in modern medicine.
